epinephrine + verapamil

Epinephrine + verapamil is a combination of two pharmacologically active agents with distinct mechanisms of action. Epinephrine is an endogenous catecholamine that acts as an agonist at alpha- and beta-adrenergic receptors, leading to increased heart rate, vasoconstriction, bronchodilation, and other sympathetic effects. It is widely used in emergency medicine for the treatment of anaphylaxis, cardiac arrest, and severe asthma exacerbations[10]. Verapamil is a phenylalkylamine calcium channel blocker that inhibits L-type calcium channels in cardiac and smooth muscle cells. This results in decreased myocardial contractility, slowed atrioventricular conduction, vasodilation, and reduced blood pressure[4][6]. The combination has been studied primarily for its electrophysiological interactions; epinephrine can reverse or attenuate the effects of verapamil on atrioventricular conduction and refractoriness[2], while verapamil can inhibit some actions of epinephrine such as platelet aggregation or arrhythmogenicity[7][5]. There are no approved fixed-dose pharmaceutical products combining these two drugs; their co-administration may occur under specific clinical circumstances but requires careful monitoring due to potential drug interactions.